Business Description
Divi's Laboratories Ltd
ISIN : INE361B01024
Share Class Description:
NSE:DIVISLAB: Ordinary SharesCompare
Compare
Traded in other countries / regions
DIVISLAB.India IPO Date
2003-03-12Description
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients with a predominance in exports. It also through its custom synthesis, supports pharma companies for their patented products business from gram scale requirements for clinical trials to launch as well as late life cycle management. Geographically, the company derives a majority of its revenue through exports to countries like the United States of America, Switzerland, and other countries.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 451 | |||||
| Equity-to-Asset | 0.88 | |||||
| Interest Coverage | 843.33 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 51.56 | |||||
| Beneish M-Score | -2.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.4 | |||||
| 3-Year EBITDA Growth Rate | -4.5 | |||||
| 3-Year EPS without NRI Growth Rate | -7 | |||||
| 3-Year FCF Growth Rate | -37.1 | |||||
| 3-Year Book Growth Rate | 13.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 17.42 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.72 | |||||
| 9-Day RSI | 38.49 | |||||
| 14-Day RSI | 43.54 | |||||
| 6-1 Month Momentum % | 31.01 | |||||
| 12-1 Month Momentum % | 63.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.24 | |||||
| Quick Ratio | 4.8 | |||||
| Cash Ratio | 2.79 | |||||
| Days Inventory | 314.85 | |||||
| Days Sales Outstanding | 88 | |||||
| Days Payable | 83.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.51 | |||||
| Dividend Payout Ratio | 0.43 | |||||
| Forward Dividend Yield % | 0.51 | |||||
| 5-Year Yield-on-Cost % | 0.51 | |||||
| Shareholder Yield % | 0.51 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.05 | |||||
| Operating Margin % | 29.54 | |||||
| Net Margin % | 21.41 | |||||
| FCF Margin % | 3.01 | |||||
| ROE % | 13.77 | |||||
| ROA % | 12.14 | |||||
| ROIC % | 17.22 | |||||
| ROC (Joel Greenblatt) % | 25.28 | |||||
| ROCE % | 18.18 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 84.59 | |||||
| Forward PE Ratio | 59.49 | |||||
| PE Ratio without NRI | 84.63 | |||||
| Shiller PE Ratio | 84.87 | |||||
| Price-to-Owner-Earnings | 258.32 | |||||
| PEG Ratio | 12.27 | |||||
| PS Ratio | 18.09 | |||||
| PB Ratio | 11.32 | |||||
| Price-to-Tangible-Book | 11.32 | |||||
| Price-to-Free-Cash-Flow | 601.86 | |||||
| Price-to-Operating-Cash-Flow | 123.14 | |||||
| EV-to-EBIT | 59.93 | |||||
| EV-to-EBITDA | 52 | |||||
| EV-to-Revenue | 17.71 | |||||
| EV-to-FCF | 587.92 | |||||
| Price-to-Projected-FCF | 7.07 | |||||
| Price-to-DCF (Earnings Based) | 5.94 | |||||
| Price-to-DCF (FCF Based) | 60.47 | |||||
| Price-to-Graham-Number | 6.53 | |||||
| Price-to-Net-Current-Asset-Value | 20.78 | |||||
| Price-to-Net-Cash | 89.29 | |||||
| Earnings Yield (Greenblatt) % | 1.67 | |||||
| FCF Yield % | 0.17 | |||||
| Forward Rate of Return (Yacktman) % | 7.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Divi's Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 85,650 | ||
| EPS (TTM) (₹) | 69.15 | ||
| Beta | 0.62 | ||
| Volatility % | 21.18 | ||
| 14-Day RSI | 43.54 | ||
| 14-Day ATR (₹) | 131.067838 | ||
| 20-Day SMA (₹) | 6007.685 | ||
| 12-1 Month Momentum % | 63.01 | ||
| 52-Week Range (₹) | 3350 - 6285.45 | ||
| Shares Outstanding (Mil) | 265.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Divi's Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Divi's Laboratories Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Divi's Laboratories Ltd Frequently Asked Questions
What is Divi's Laboratories Ltd(NSE:DIVISLAB)'s stock price today?
The current price of NSE:DIVISLAB is ₹5849.45. The 52 week high of NSE:DIVISLAB is ₹6285.45 and 52 week low is ₹3350.00.
When is next earnings date of Divi's Laboratories Ltd(NSE:DIVISLAB)?
The next earnings date of Divi's Laboratories Ltd(NSE:DIVISLAB) is 2025-02-10 Est..
Does Divi's Laboratories Ltd(NSE:DIVISLAB) pay dividends? If so, how much?
The Dividend Yield %  of Divi's Laboratories Ltd(NSE:DIVISLAB) is 0.51% (As of Today), Highest Dividend Payout Ratio of Divi's Laboratories Ltd(NSE:DIVISLAB) was 0.64. The lowest was 0.18. And the median was 0.37. The  Forward Dividend Yield % of Divi's Laboratories Ltd(NSE:DIVISLAB) is 0.51%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers